Comparative Pharmacology
Head-to-head clinical analysis: DESOGEN versus LARIN FE 1 5 30.
Head-to-head clinical analysis: DESOGEN versus LARIN FE 1 5 30.
DESOGEN vs LARIN FE 1.5/30
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progestin (desogestrel) combined with ethinyl estradiol inhibits gonadotropin release, suppressing ovulation. Also increases cervical mucus viscosity, impeding sperm penetration.
Combination oral contraceptive containing ethinyl estradiol (estrogen) and norethindrone (progestin). Suppresses gonadotropin release (FSH, LH) via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation. Increases cervical mucus viscosity, reducing sperm penetration; alters endometrial receptivity. Norethindrone also decreases ovarian estrogen production.
One tablet (0.15 mg desogestrel and 0.03 mg ethinyl estradiol) orally once daily for 21 consecutive days, followed by 7 hormone-free days.
One tablet orally once daily for 21 consecutive days, followed by 7 placebo tablets.
None Documented
None Documented
The terminal elimination half-life of etonogestrel is approximately 30-41 hours. This long half-life supports once-daily dosing for contraceptive efficacy.
Ethinyl estradiol terminal half-life is approximately 13-17 hours; norethindrone terminal half-life is approximately 7-10 hours. Steady-state is reached within 5-10 days.
Desogestrel is primarily metabolized to its active metabolite etonogestrel, which is extensively metabolized and excreted as conjugates. About 50-60% is excreted via urine and 30-40% via feces. Less than 1% is excreted unchanged.
Ethinyl estradiol and norethindrone are primarily excreted via renal (urine) and fecal routes. Approximately 40-50% of ethinyl estradiol is excreted renally as metabolites, with 20-30% in feces. Norethindrone metabolites are excreted ~50-70% renally and 20-30% fecally. Less than 5% is excreted unchanged.
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive